HOPA Now is the official podcast of the Hematology/Oncology/Pharmacy Association, an organization dedicated to supporting pharmacy practitioners and promoting the advancement of Hematology/Oncology/Pharmacy to optimize the care of individuals impacted by cancer.

 

These educational podcasts are part of our BCOP Preparatory and Recertification Course, which is designed to prepare oncology pharmacists preparing to sit for the BCOP Certification Exam, as well as meet the BPS requirement to complete a BCOP Preparatory/Recertification Review Course.

 

In this episode of HOPA Now, Dr. Allison Duffy explores NCCN preferred first-line treatment options, explains medication dosage guidelines for various forms of leukemia and offers an overview of the potential side effects that may result from different management recommendations. She concludes with a look at potential future relapse rates based on patient adherence to medication guidelines.

 

In this episode you will learn:

 

Screening and prevention information

• NCCN preferred first-line treatment options
• Guidance for medication dosages
• CLL inhibitor side effects and management recommendations
• Understanding CLL evaluation of response
• A look at hairy cell leukemia and CML progressive disease
• CML toxicity and supportive care management

 

Mentioned in This Episode:

HOPA

NCCN Clinical Practice Guidelines

 

Tweetables:

 

“Regardless of patient factors, there are three NCCN preferred first-line treatment options.” — Allison Duffy

 

“Greater than 85% adherence is tied to a higher probability of achieving complete cytogenetic remission at two years.” — Allison Duffy